Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, 2-Arm, Double-Blind Study of AT-101 in Combination With Docetaxel Versus Docetaxel Plus Placebo in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)

NCT00544960 is registered in ClinicalTrials.gov with Ascenta Therapeutics as lead sponsor.

NCT NCT00544960
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00544960 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, 2-Arm, Double-Blind Study of AT-101 in Combination With Docetaxel Versus Docetaxel Plus Placebo in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer (NSCLC)
Lead sponsor
Ascenta Therapeutics
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2007
Completion date
April 30, 2009
Enrollment
106 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer